Cell-type-specific activation of mitogen-activated protein kinases in PAN-induced progressive renal disease in rats

Sang-Joon Park1, Kyu-Shik Jeong

  • 1College of Veterinary Medicine, Kyungpook National University, Daegu 702-701, Republic of Korea.

Insights

Mitogen-activated protein (MAP) kinases, including JNK, ERK, and p38, are activated during puromycin aminonucleoside (PAN)-induced kidney disease. Their activation in renal and inflammatory cells contributes to glomerulosclerosis and fibrosis.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Cell Biology

Background:

  • Puromycin aminonucleoside (PAN) induces renal disease, characterized by glomerular and tubulointerstitial damage.
  • Mitogen-activated protein (MAP) kinases are crucial signaling molecules involved in cellular responses to injury.

Purpose of the Study:

  • To investigate the time-course activation and cell-type specific roles of JNK, ERK, and p38 MAP kinases in PAN-induced renal disease.
  • To elucidate the involvement of MAP kinases in the pathogenesis of glomerulosclerosis and tubulointerstitial fibrosis.

Main Methods:

  • PAN was administered to induce renal disease in a rodent model.
  • Immunohistochemistry was used to detect the activation and localization of phosphorylated JNK, ERK, and p38.
  • Time-course analysis of MAP kinase activation was performed.

Main Results:

  • Maximal activation of JNK, ERK, and p38 occurred at specific time points post-PAN treatment (Days 5, 3, and 3, respectively).
  • Activated JNK was found in mesangial, proximal tubular, and inflammatory cells.
  • Activated ERK was prominent in glomerular regions and macrophages, while activated p38 was observed in glomerular endothelial cells, tubular cells, and inflammatory cells.

Conclusions:

  • MAP kinase activation in renal native cells during early injury is linked to cellular proliferation and apoptosis.
  • MAP kinase activation in inflammatory and fibrotic cells plays a significant role in the development of glomerulosclerosis and tubulointerstitial fibrosis.
  • Targeting MAP kinase pathways may offer therapeutic potential for mitigating kidney damage in related diseases.